Increased expression of mdig predicts poorer survival of the breast cancer patients

Gene

Volumn 535, Issue 2, 2014, Pages 218-224

  Thakur, Chitra ^a   Lu, Yongju ^a   Sun, Jiaying ^a,b   Yu, Miaomiao ^a,b,c   Chen, Bailing ^a   Chen, Fei ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

^c LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Breast cancer; Mdig; Patient survival; Prognosis

Indexed keywords

MESSENGER RNA;

ADENOID CYSTIC CARCINOMA; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; GENE EXPRESSION; HISPANIC; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MDIG GENE; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DOMAIN; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; UNITED STATES;

ACC; ADENOID CYSTIC CARCINOMA; BRCA1; BREAST CANCER; BREAST CANCER 1 GENE; DCIS; DISTANT METASTASIS FREE SURVIVAL; DMFS; DUCTAL CARCINOMA IN SITU; HORMONE REPLACEMENT THERAPY; HRT; IDC; ILC; INVASIVE DUCTAL CARCINOMA; INVASIVE LOBULAR CARCINOMA; MDIG; MINERAL DUST-INDUCED GENE; OS; OVERALL SURVIVAL; PATIENT SURVIVAL; POST-PROGRESSION SURVIVAL; PPS; PROGNOSIS; RELAPSE FREE SURVIVAL; RFS;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ORDER; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS;

EID: 84891152528     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.11.031     Document Type: Article

References (26)

1. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann. Oncol. 2012, 23(Suppl. 6):vi7-vi12.
2. Chen B., et al. Mdig de-represses H19 large intergenic non-coding RNA (lincRNA) by down-regulating H3K9me3 and heterochromatin. Oncotarget 2013, 4:1427-1437.
3. Dowsett M., et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl. Cancer Inst. 2011, 103:1656-1664.
4. Eilbracht J., Kneissel S., Hofmann A., Schmidt-Zachmann M.S. Protein NO52-A constitutive nucleolar component sharing high sequence homologies to protein NO66. Eur. J. Cell Biol. 2005, 84:279-294.
5. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46:765-781.
6. Fukahori S., et al. Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma. J. Pediatr. Surg. 2007, 42:1831-1840.
7. Ge W., et al. Oxygenase-catalyzed ribosome hydroxylation occurs in prokaryotes and humans. Nat. Chem. Biol. 2012, 8:960-962.
8. Gyorffy B., et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 2010, 123:725-731.
9. Inwald E.C., et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res. Treat. 2013, 139:539-552.
10. Ishizaki H., et al. Overexpression of the myc target gene Mina53 in advanced renal cell carcinoma. Pathol. Int. 2007, 57:672-680.
11. Jacquemier J., et al. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res. 2009, 11:R23.
12. Kooistra S.M., Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat. Rev. Mol. Cell Biol. 2012, 13:297-311.
13. Lee M.C., Joh J.E., Chau A. Axillary staging prior to neoadjuvant chemotherapy: the roles of sentinel lymph node biopsy and axillary ultrasonography. Cancer Control 2012, 19:277-285.
14. Lu Y., et al. Lung cancer-associated JmjC domain protein mdig suppresses formation of tri-methyl lysine 9 of histone H3. Cell Cycle 2009, 8:2101-2109.
15. Marchionni L., Afsari B., Geman D., Leek J.T. A simple and reproducible breast cancer prognostic test. BMC Genomics 2013, 14:336.
16. Maxwell K.N., Domchek S.M. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat. Rev. Clin. Oncol. 2012, 9:520-528.
17. Ogasawara S., Komuta M., Nakashima O., Akiba J., Tsuneoka M., Yano H. Accelerated expression of a Myc target gene Mina53 in aggressive hepatocellular carcinoma. Hepatol. Res. 2010, 40:330-336.
18. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
19. Tan X.P., Zhang Q., Dong W.G., Lei X.W., Yang Z.R. Upregulated expression of Mina53 in cholangiocarcinoma and its clinical significance. Oncol. Lett. 2012, 3:1037-1041.
20. Teye K., et al. Increased expression of a Myc target gene Mina53 in human colon cancer. Am. J. Pathol. 2004, 164:205-216.
21. Tran B., Bedard P.L. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 2011, 13:221.
22. Tsuneoka M., Koda Y., Soejima M., Teye K., Kimura H. A novel myc target gene, mina53, that is involved in cell proliferation. J. Biol. Chem. 2002, 277:35450-35459.
23. Tsuneoka M., et al. Mina53 as a potential prognostic factor for esophageal squamous cell carcinoma. Clin. Cancer Res. 2004, 10:7347-7356.
24. Yu M., Sun J., Chen B., Lu Y., Zhao H., Chen F. Paradoxical roles of mineral dust induced gene expression on cell proliferation and migration/invasion. Cell Cycle 2013, (under review).
25. Zhang Y., et al. The Human mineral dust-induced gene, mdig, is a cell growth regulating gene associated with lung cancer. Oncogene 2005, 24:4873-4882.
26. Zhang Q., Hu C.M., Yuan Y.S., He C.H., Zhao Q., Liu N.Z. Expression of Mina53 and its significance in gastric carcinoma. Int. J. Biol. Markers 2008, 23:83-88.